Key Takeaway
Preclinical and human studies strongly support CBD as a treatment for anxiety disorders, with acute doses of 300-600mg reducing experimentally induced anxiety
Summary
This comprehensive review examined evidence from preclinical, human experimental, clinical, and epidemiological studies on CBD for anxiety. The authors found consistent anxiolytic effects across multiple anxiety paradigms and disorders, supporting CBD as a promising treatment option.
Methods
- Design: Systematic review of existing literature
- Scope: Preclinical (animal) and human studies
- Focus: Generalized anxiety, social anxiety, panic, OCD, PTSD
- Examined: Mechanisms of action, dosing, safety profile
- Databases: PubMed, Web of Science, PsycINFO
Key Results
- Preclinical studies: Consistent anxiolytic effects in animal models
- Human experimental studies:
- 300-600mg CBD reduced experimentally induced anxiety
- Public speaking studies showed significant anxiety reduction
- Effects comparable to conventional anxiolytics
- Mechanisms identified:
- 5-HT1A receptor agonism (serotonin)
- Modulation of endocannabinoid system
- Effects on amygdala and prefrontal cortex
- Well-tolerated with minimal side effects
- No psychoactive or addictive properties
Limitations
- Many studies used acute (single dose) administration
- Limited chronic dosing studies at time of review
- Heterogeneous dosing across studies
- Most clinical trials were small sample sizes
- Optimal dosing not yet established